Drugs / ROMILKIMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01529853 | Jan 2012 → Oct 2013 | idiopathic pulmonary fibrosis | Sanofi | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT02921971 | Dec 2016 → Jan 2019 | systemic sclerosis | Sanofi | Completed | Met primary |
| Phase 2 | NCT02345070 | May 2015 → May 2017 | idiopathic pulmonary fibrosis | Sanofi | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROMILKIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298097 ↗ |
| Known as | Hutbti3_2_1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298097 ↗ |
| Known as | SAR156597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01529853 ↗ |
| Action | Inhibit | “binds and neutralises IL-4/IL-13” PMID 32963047 ↗ Sep 2020 |
| Modality | Monoclonal antibody | “Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody” PMID 32963047 ↗ Sep 2020 |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT01529853 ↗ |
| Target | IL13 | “Interleukin-13 inhibitor” CHEMBL4298097 ↗ |
| Target | IL4 | “Interleukin-4 inhibitor” CHEMBL4298097 ↗ |